A number of A-listers have shared their experience of taking the jab

Ozempic is the brand name for semaglutide, a once-weekly injectable drug developed by Novo Nordisk. Belonging to the GLP-1 receptor agonist (GLP-1 RA) class, it mimics a natural hormone that helps regulate blood sugar. By boosting insulin release when glucose is high, suppressing glucagon, slowing digestion, and reducing appetite, Ozempic improves glycemic control and often leads to modest weight loss.

**Regulatory Status:**
The U.S. FDA approved Ozempic in 2017 as an add-on to diet and exercise for adults with type 2 diabetes. It is *not* FDA-approved for weight management. In the UK and EU, it is also authorized only for type 2 diabetes. For obesity, the higher-dose version Wegovy (semaglutide 2.4 mg weekly) is specifically approved. Using Ozempic strictly for weight loss is considered off-label prescribing.

**Mechanism of Action:**
Semaglutide works in four main ways: it increases glucose-dependent insulin release, suppresses excess glucagon, slows gastric emptying (keeping you fuller longer), and acts on the brain’s appetite centers to reduce cravings.

**Comparisons:**

* *Ozempic* (0.5–1 mg): diabetes control, \~4–6% weight loss.
* *Wegovy* (2.4 mg): obesity treatment, \~10–15% weight loss.
* *Mounjaro* (tirzepatide): dual GLP-1/GIP agonist, showing up to 20% weight loss.

**Misconceptions:**
Ozempic is often mistaken for a weight-loss drug, widely available, or risk-free. In reality, it carries side effects—most commonly nausea, vomiting, and diarrhea—and is not a substitute for healthy lifestyle changes.

**Bottom line:** Ozempic is a valuable tool for managing type 2 diabetes. While it can aid weight loss, only Wegovy and Mounjaro are approved for obesity. Proper use requires medical guidance, clear expectations, and ongoing monitoring.